At the end, samples were incubated for 10 min at 72 C
Disclosures: Yashbir Singh: Nothing to Disclose, John Eaton: Nothing to Disclose, Sudhakar Venkatesh: Nothing to Disclose, Shahriar Faghani: Nothing to Disclose, Mette vesterhus: Nothing to Disclose, Tom Karlsen: Nothing to Disclose, Kristin Jorgensen: Nothing to Disclose, Trine Folseraas: Nothing to Disclose, Kosta Petrovic: Nothing to Disclose, Anne Negrd: Nothing to Disclose, Aliya Gulamhusein: Advanz: Consultant, Cymabay: Consultant, Gregory Gores: Nothing to Disclose, Sumera Ilyas: Astrazeneca: Consultant, Timucin Taner: Nothing to Disclose, Julie Heimbach: Nothing to Disclose, Nicholas LaRusso: NIH: R01 DK 24031, NIH: R01 DK 57993, NIH: P30 DK 84567, NIH: P30 DK90728, NIH: R01 DK117133, NIH: T32 DK 07198, Konstantinos Lazaridis: Nothing to Disclose, Bradley Erickson: Nothing to Disclose 2341 THE PREVALENCE OF INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE (IFALD) IN PATIENTS ON LONG-TERM HOME PARENTERAL NUTRITION Nicholas Wan 1 Sharifah Syed Mustaffah 2 Andrew Holt 2 Richard Woodman 3 Shailesh Bihari 2 Steven Galluccio 2 Sumudu Narayana 2 Qun Chen 2 Maria Kielpikowska 2 Kate Muller 2 Jeyamani Ramachandran 2 Rachel Wundke 2 Rosalie Altus 2 Alan Wigg 2 , 1 Lyell McEwin Hospital, 2 Flinders Medical Centre, 3 Flinders University Background: Intestinal failure-associated liver disease (IFALD) is a recognized complication of long-term parenteral nutrition (PN)
Park EY, Shimura N, Konishi T, et al
The same was observed with COVID-19 with the involvement of IgG antibodies and Fc receptor of immune cells [153,154]
